Aurobindo Pharma USA, Inc. (“Aurobindo USA”), a wholly owned subsidiary of the Aurobindo Pharma Limited, earlier in this week had announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition deal of Lannett Company LLC (“Lannett”). The Company announced this deal by issuing a press release towards their investors, and market regulators.
Lannett Company LLC is a Pennsylvania-based pharmaceutical company specializing in the development and commercialization of complex generic pharmaceutical products, including non-opioid controlled substances.
The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026. The acquisition will significantly expand Aurobindo USA’s product offering in this segment while adding a U.S.-based manufacturing facility to its network.
Lannett’s manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, will strengthen Aurobindo USA’s domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production. The transaction is expected to be immediately accretive to Aurobindo Group’s earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company’s portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.
Written by: Pramit Hazra
Graphics by: Pramit Hazra
